US-based biopharmaceutical services provider Parexel International has expanded and fully integrated its commercialisation services to address demand for product value that stretches right along the clinical development, regulatory and market access chain.
“Biopharmaceutical companies need to address commercialisation goals as early as possible to develop products and acquire the right data to receive reimbursement approval in the most efficient way,” says Gadi Saarony, corporate vice president and worldwide head, Parexel Consulting and Medical Communications Services.
Parexel’s commercialisation services, which include market access strategies, payer communications, publication strategies, health outcomes analyses and economic modelling, have been fully integrated to help clients maximise regional and global market access opportunities, the company explains.
These services are designed to meet the evolving needs of biopharmaceutical companies’ health economics and outcomes research, medical affairs, marketing, reimbursement and managed markets departments, Parexel adds, citing its global network of key opinion leaders and database of global clinical trial experiences.
Alignment and integration
“We help clients prepare the product for the market and the market for the product through the alignment and integration of regulatory, clinical and commercialisation strategies,” Saarony comments.
“Among the key advantages we offer to clients is that as a CRO [contract research organisation] we can draw on our experience developing products across all phases and a broad range of therapeutic areas to inform their commercialisation strategies with meaningful scientific and clinical considerations.”
The Commercialization Services team includes experts located across four continents and a “cadre” of former biopharmaceutical industry leaders, scientific researchers, regulators, and medical writers, as well as product development and management experts, Parexel notes.
The views expressed in the following comments are not those of PharmaTimes or any connected third party and belong specifically to the individual who made that comment. We accept no liability for the comments made and always advise users to exercise caution.